STIM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Neuronetics Inc (STIM) does not currently present a strong buy opportunity for a beginner investor with a long-term strategy. While the company has shown significant revenue growth, its declining net income, EPS, and gross margin raise concerns about profitability. Additionally, the absence of strong trading signals, neutral sentiment from insiders and hedge funds, and a lack of recent congress trading data suggest limited immediate upside potential. Given the investor's preference for long-term growth, it may be better to monitor the stock for improved financial performance or clearer positive catalysts before investing.
The MACD is positive and expanding, suggesting bullish momentum. RSI is neutral at 68.103, and moving averages are converging, indicating no clear trend. The stock is trading near its resistance level (R1: 1.489), with key support at 1.214. Overall, the technical indicators suggest a cautious stance as there is no strong breakout signal.
Revenue growth of 85.73% YoY in Q4
Appointment of a new CEO, Dan Reuvers, which could bring strategic changes and growth opportunities.
Collaboration with Compass Pathways (CMPS) announced during the earnings call.
Declining net income (-43.47% YoY) and EPS (-70.59% YoY) in Q4
Gross margin dropped by 21.54% YoY, indicating profitability challenges.
Pre-market price decline of -3.63%, reflecting weak immediate sentiment.
In Q4 2025, revenue increased significantly by 85.73% YoY to $41.78 million. However, net income dropped to -$7.16 million (-43.47% YoY), and EPS fell to -$0.10 (-70.59% YoY). Gross margin also declined to 51.95% (-21.54% YoY), highlighting profitability concerns despite strong revenue growth.
Canaccord maintains a Buy rating but lowered the price target from $7 to $3, citing in-line Q4 results and guidance. The firm's optimism stems from the new CEO appointment and operational cash flow positivity in Q2, but the reduced price target reflects tempered expectations.
